Final safety and efficacy analysis of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer

Maass N, Schem C, Bauerschlag DO, Tiemann K, Schaefer FW, Hanson S, Muth M, Baier M, Weigel MT, Wenners AS, Alkatout I, Bauer M, Jonat W, Mundhenke C (2014)

Publication Type: Journal article

Publication year: 2014

Journal

Oncology Karger

Book Volume: 87

Pages Range: 300-310

Journal Issue: 5

DOI: 10.1159/000365553

Abstract

Background: Imatinib is a tyrosine kinase inhibitor of BCR-ABL, ABL, PDGFR-α and -β, KIT, and DDR. In solid tumors, it inhibits proliferation and invasiveness and facilitates higher intratumoral cytotoxic drug concentrations. Vinorelbine has good tolerability and efficacy in metastatic breast cancer (MBC). This study evaluates the safety and efficacy of imatinib and vinorelbine in combination.

Authors with CRIS profile

Christoph Mundhenke

Involved external institutions

Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen DE Germany (DE) Christian-Albrechts-Universität zu Kiel DE Germany (DE) Dres Tiemann & Schulte Partnerschaft Institut für Hämatopathologie Hamburg DE Germany (DE) Novartis AG CH Switzerland (CH)

How to cite

APA:

Maass, N., Schem, C., Bauerschlag, D.O., Tiemann, K., Schaefer, F.W., Hanson, S.,... Mundhenke, C. (2014). Final safety and efficacy analysis of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer. Oncology, 87(5), 300-310. https://dx.doi.org/10.1159/000365553

MLA:

Maass, Nicolai, et al. "Final safety and efficacy analysis of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer." Oncology 87.5 (2014): 300-310.

BibTeX: Download